A bout 40% of Americans will develop cancer in their lifetimes (1) . In addition, more than 13 million Americans currently live with invasive cancer and this number will likely increase over time as continued advances in cancer treatments lead to longer survival (1) . Patients with cancer face an increased risk of medical complications, especially venous thromboembolism, which is increased roughly 7-fold in patients with cancer and affects up to 20% of the cancer population (2, 3) . Reasons for this heightened risk include frequent immobility, invasive procedures, and alterations in coagulation, platelet, and endothelial function (3) . Nevertheless, despite these well-known alterations in clotting function and the greatly heightened risk of venous thromboembolism, incident cancer is not an established independent risk factor for arterial thromboembolism, and patients with cancer do not routinely receive therapies to prevent myocardial infarction and stroke (4-6).
Ischemic heart disease and stroke are leading causes of death and disability worldwide (7) . Clinical series have suggested that these arterial thromboembolic events may be common in patients with cancer (8) (9) (10) (11) (12) . Population-based data, however, are scarce regarding the association between cancer, broadly defined, and arterial thromboembolism, with most previous investigations focused on individual cancer types or specific arterial events (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . In addition, the effect of cancer stage on arterial thromboembolism risk is uncertain, as is the impact of arterial thromboembolism on the survival of patients with cancer. Therefore, we aimed to define these epidemiological relationships by using population-based Medicare claims data to evaluate the risk of myocardial infarction and ischemic stroke in patients with new diagnoses of the most common solid and hematologic cancers. Our hypothesis was that a new diagnosis of cancer is associated with an (27) . Similarly, we chose non-Hodgkin lymphoma because it is the most common hematologic cancer (27) . We also included pancreatic and gastric cancers because these cancers are thought to carry the highest risk of venous thromboembolism (28) . In total, these 8 cancers account for approximately 64% of all incident malignant cancer in the United States (27) . Patients who were diagnosed with multiple primary cancers during the study period were assigned the cancer type diagnosed first.
We used site record definitions from the SEER Patient Entitlement and Diagnosis Summary File to define our cancer cohorts (27) . The specific site definitions used to define our cancer cohorts are based on NHL ¼ non-Hodgkin lymphoma.
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Arterial or mesenteric ischemia in our composite outcome because these are uncommon events that lack validated diagnostic codes.
ANALYSIS. Descriptive statistics were used to evaluate baseline characteristics. As death is a frequent competing risk in patients with cancer and can prevent arterial thromboembolic events from being observed, competing risk survival statistics accounting for death were used to calculate the cumulative incidence of arterial thromboembolism (32) . Visual inspection of the cumulative incidence curves, as well as formal statistical testing, demonstrated that the risks of arterial thromboembolism in the cancer groups varied over time, meaning that the proportional hazards assumption was violated.
Therefore, hazard ratios (HRs) were not calculated for the entirety of patient follow-up, but rather during discrete time periods for which the proportional hazards assumption was generally met. The Navi et al.
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To estimate a global summary statistic for cancer in general, while also accounting for variable risks across individual cancer types, we analyzed data for each of the 8 cancer types separately and in combination. Follow-up was calculated from the case patient's date of cancer diagnosis until myocardial infarction, ischemic stroke, death, or end of study on December 31, 2012 (whichever occurred first).
Myocardial infarction, ischemic stroke, and deaths were considered events, and patients without these events were censored.
In subgroup analyses aiming to evaluate the effects of cancer stage on arterial thromboembolism risk, the cumulative incidence function was strati- In a post hoc sensitivity analysis, we used inpatient and outpatient Medicare claims data in the year before study entry to evaluate differences in the frequency of cardiovascular risk factors between groups. We determined that peripheral vascular Pancreas 5.0 (3.6-6.9) 2.6 (2.0-3.4)
Values are hazard ratio (95% confidence interval). *Data are shown through the median period of follow-up for each cancer type up to a maximum of 1 yr.
NHL ¼ non-Hodgkin lymphoma.
Arterial Thromboembolism in Cancer Patients disease, chronic kidney disease, chronic obstructive pulmonary disease, valvular disease, and liver disease were more common among patients with cancer, whereas diabetes mellitus and congestive heart failure were more common among control patients.
To account for these differences, we performed an additional analysis whereby cancer cases and cancer-free control patients were matched by these 7 cardiovascular risk factors, in addition to the variables previously matched by in our primary analysis. 
common than myocardial infarction, but the HR for myocardial infarction was consistently higher than for ischemic stroke (Figure 1, Table 4 ). The 6-month cumulative incidence of myocardial infarction was 2.0% (95% CI: 1.9% to 2.0%) in all patients with cancer compared with 0.7% (95% CI: 0.6% to 0.7%) in control patients (HR: 2.9; 95% CI: 2.8 to 3.1; p < 0.001). The 6-month cumulative incidence of ischemic stroke was 3.0% (95% CI: 2.9% to 3.1%) in all patients with cancer compared with 1.6% (95% CI: 1.6% to 1.7%) in control patients (HR: 1.9; 95% CI: 1.8 to 2.0; p < 0.001). Among the different cancer types, patients with lung cancer had the highest 6-month cumulative incidence of myocardial infarction (3.2%; 95% CI: 3.0% to 3.3%) and ischemic stroke (5.6%; 95% CI: 5.4% to 5.7%). Excess risks of both myocardial infarction and ischemic stroke KNOWLEDGE. An increased risk of cardiovascular events has been previously reported in patients with lymphoma and breast, lung, cervical, prostate, gastric, ovarian, and head and neck cancers (13) (14) (15) (16) (17) (18) (19) (20) . Among Swedish patients diagnosed with any cancer type between 1987 and 2009, the 6-month relative risk of an inpatient diagnosis of coronary heart disease was 1.7 (21) , and the 6-month relative risk of an inpatient diagnosis of ischemic stroke was 1.6 (26) . In these Swedish studies, most individual cancer types were associated with an increased risk of arterial thromboembolism, including hematologic cancers and non-smokingrelated solid cancers, although, similar to our study, the risks were highest with generally more advanced cancer types. Our study builds on these prior reports by including data on outpatients, cancer stage, and mortality after arterial thromboembolism, and by performing detailed individual matching to minimize the risk of confounding bias in a large, demographically heterogeneous population. 
CONCLUSIONS
We found that patients with a new diagnosis of cancer faced an increased risk of arterial thromboembolism, especially during the first 6 months after diagnosis.
Our results suggest that malignant cancer may be an underappreciated, yet common risk factor for arterial thromboembolism. Future research should aim to investigate the mechanistic basis for these findings, the utility of including cancer in cardiovascular risk prediction instruments, and optimal strategies to prevent arterial thromboembolism in patients with cancer. Navi et al.
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